Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Tourette Syndrome Treatment Market

Tourette Syndrome Treatment Market Trends

Report ID: GMI10872
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Tourette Syndrome Treatment Market Trends

The growing prevalence of neurological disorders, notably Tourette syndrome, is a significant driver of the market.
With rising awareness and diagnosis of neurological conditions, an increasing number of individuals are being recognized as having Tourette syndrome.
For example, in 2023, estimates suggest that Tourette syndrome (TS) affects roughly 0.5% to 1% of the global population, with noted differences between adults and children. Specifically, studies indicate a prevalence of about 0.6% in children, while the general population sees rates between 0.5% and 1%.
This uptick in incidence is fueling a heightened demand for effective treatment avenues, spanning pharmacological therapies, behavioral interventions, and novel emerging therapies.
Moreover, a growing acknowledgment of Tourette syndrome's effects on quality of life is spurring increased investments in research and development, further driving the market's expansion.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

In 2023, the Tourette syndrome treatment industry was valued at USD 2.4 billion and is projected to grow at a CAGR of 4.8% from 2024 to 2032. The market's growth is primarily fueled by the rising incidence of Tourette syndrome, a trend largely linked to enhanced diagnostic capabilities and increased awareness.

In 2023, motor tics segment commanded a dominant market share of 63.5%, owing to widespread occurrence of motor tics in TS patients, coupled with the need for a diverse range of specialized treatments aimed at alleviating symptoms and enhancing the quality of life.

By 2032, North American Tourette syndrome treatment industry is projected to reach USD 1.5 billion, growing at a CAGR of 5%, due to its advanced healthcare infrastructure and ongoing neurological disorder research.

Some notable medicine manufacturers include AstraZeneca PLC, Bausch Health Companies Inc., Catalyst Pharmaceuticals, Inc., Eli Lilly and Company, Emalex Biosciences, Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., and Sun Pharmaceutical Industries Limited among others.